How Sites Can Win In The New Age of Genetically Engineered Treatments

By James Riddle, Vice President, Research Services & Strategic Consulting

The promise of gene therapy treatments is upon us. In more than 20 years of experience in the clinical research space, I heard a lot of excitement over the years about genetically engineered treatments. In the last few years, that excitement has begun translating into reality. We see an accelerating gene therapy market, expected to grow globally by 16.6 percent between 2020-2027. Early phase research may be conducted in the halls of large academic medical centers who are equipped and experienced in working with genetically engineered treatments and biosafety requirements. However, all those new therapies must eventually go through larger scale clinical trials on their way to market approval. As gene therapies enter the pipeline at an exponentially-growing pace, how can private and hospital-based clinical trial sites prepare themselves to take advantage of the coming rush?

In this blog, we will explore how proactive clinical research sites, from small private clinics to large integrated health systems, are preparing for the accelerated trend of gene therapy research.